Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
|Study Number||Lead Group||Study Title||CIRB||Study Status|
|A221505||Alliance||Phase III Randomized Trial of Hypofractionated Post Mastectomy Radiation with Breast Reconstruction||Cancer Prevention and Control CIRB||Available to Open|
|A031501||Alliance||Phase III Randomized Adjuvant Study of MK-3475 (Pembrolizumab) in Muscle Invasive and Locally Advanced Urothelial Carcinoma (Ambassador) Versus Observation||Adult CIRB - Late Phase Emphasis||Available to Open|
|A081801||Alliance||Integration of Immunotherapy into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO||Adult CIRB - Late Phase Emphasis||Available to Open|
|A091404||Alliance||A Phase II Study of Enzalutamide (NSC# 766085) for Patients with Androgen Receptor Positive Salivary Cancers||Adult CIRB - Late Phase Emphasis||Available to Open|
|A021806||Alliance||A Phase III Trial of Perioperative versus Adjuvant Chemotherapy for Resectable Pancreatic Cancer||Adult CIRB - Late Phase Emphasis||Available to Open|
|A231602CD||Alliance||Assessing Financial Difficulty in Patients with Blood Cancers||Cancer Prevention and Control CIRB||Available to Open|
|A011401||Alliance||Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer||Adult CIRB - Late Phase Emphasis||Available to Open|
|A031803||Alliance||Phase II Trial of Intravesical Gemcitabine and MK-3475 (pembrolizumab) in the Treatment of Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer||Adult CIRB - Late Phase Emphasis||Available to Open|
|A051701||Alliance||Randomized Phase II/III Study of Venetoclax (ABT 199) Plus Chemoimmunotherapy for MYC/BCL2 Double-Hit and Double-Expressing Lymphomas||Adult CIRB - Late Phase Emphasis||Available to Open|
|A091105||Alliance||A Phase III; Double Blind; Randomized; Placebo-Controlled Trial of Sorafenib in Desmoid Tumors or Aggressive Fibromatosis (DT/DF)||Adult CIRB - Late Phase Emphasis||Available to Open|